Prothena Stock (NASDAQ:PRTA)
Previous Close
$14.04
52W Range
$11.70 - $41.55
50D Avg
$15.85
200D Avg
$20.48
Market Cap
$643.01M
Avg Vol (3M)
$556.99K
Beta
0.16
Div Yield
-
PRTA Company Profile
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
PRTA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| SCPH | scPharmaceuticals Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| MCRB | Seres Therapeutics, Inc. |
| NUVL | Nuvalent, Inc. |
| KNSA | Kiniksa Pharmaceuticals, Ltd. |
| VRDN | Viridian Therapeutics, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| IMCR | Immunocore Holdings plc |
| ONCY | Oncolytics Biotech Inc. |
| ETNB | 89bio, Inc. |
| PCVX | Vaxcyte, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| ACLX | Arcellx, Inc. |
| MIST | Milestone Pharmaceuticals Inc. |